JP2020502150A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502150A5
JP2020502150A5 JP2019532017A JP2019532017A JP2020502150A5 JP 2020502150 A5 JP2020502150 A5 JP 2020502150A5 JP 2019532017 A JP2019532017 A JP 2019532017A JP 2019532017 A JP2019532017 A JP 2019532017A JP 2020502150 A5 JP2020502150 A5 JP 2020502150A5
Authority
JP
Japan
Prior art keywords
plasminogen
pharmaceutical composition
use according
drug
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502150A (ja
JP7175270B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/089066 external-priority patent/WO2018107706A1/zh
Publication of JP2020502150A publication Critical patent/JP2020502150A/ja
Publication of JP2020502150A5 publication Critical patent/JP2020502150A5/ja
Priority to JP2022119543A priority Critical patent/JP2022166026A/ja
Application granted granted Critical
Publication of JP7175270B2 publication Critical patent/JP7175270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532017A 2016-12-15 2017-06-19 グルカゴン、インスリンを正常なバランスに戻らせる方法 Active JP7175270B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022119543A JP2022166026A (ja) 2016-12-15 2022-07-27 グルカゴン、インスリンを正常なバランスに戻らせる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110171 2016-12-15
CNPCT/CN2016/110171 2016-12-15
PCT/CN2017/089066 WO2018107706A1 (zh) 2016-12-15 2017-06-19 一种使胰高血糖素、胰岛素恢复正常平衡的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022119543A Division JP2022166026A (ja) 2016-12-15 2022-07-27 グルカゴン、インスリンを正常なバランスに戻らせる方法

Publications (3)

Publication Number Publication Date
JP2020502150A JP2020502150A (ja) 2020-01-23
JP2020502150A5 true JP2020502150A5 (https=) 2020-07-30
JP7175270B2 JP7175270B2 (ja) 2022-11-18

Family

ID=62557852

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019532017A Active JP7175270B2 (ja) 2016-12-15 2017-06-19 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2019532019A Active JP7554557B2 (ja) 2016-12-15 2017-06-19 インスリン受容体基質－２の発現を促進する方法
JP2019531895A Active JP7171572B2 (ja) 2016-12-15 2017-06-19 糖尿病を治療するための新しい方法
JP2019532043A Active JP7554048B2 (ja) 2016-12-15 2017-06-19 インスリン分泌を促進する方法
JP2022119543A Pending JP2022166026A (ja) 2016-12-15 2022-07-27 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2022119582A Pending JP2022166028A (ja) 2016-12-15 2022-07-27 インスリン受容体基質－２の発現を促進する方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019532019A Active JP7554557B2 (ja) 2016-12-15 2017-06-19 インスリン受容体基質－２の発現を促進する方法
JP2019531895A Active JP7171572B2 (ja) 2016-12-15 2017-06-19 糖尿病を治療するための新しい方法
JP2019532043A Active JP7554048B2 (ja) 2016-12-15 2017-06-19 インスリン分泌を促進する方法
JP2022119543A Pending JP2022166026A (ja) 2016-12-15 2022-07-27 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2022119582A Pending JP2022166028A (ja) 2016-12-15 2022-07-27 インスリン受容体基質－２の発現を促進する方法

Country Status (9)

Country Link
US (4) US11129880B2 (https=)
EP (4) EP3556384B1 (https=)
JP (6) JP7175270B2 (https=)
CN (4) CN110198732A (https=)
CA (4) CA3047172A1 (https=)
DK (1) DK3556383T5 (https=)
ES (1) ES2981141T3 (https=)
TW (7) TW201822803A (https=)
WO (7) WO2018107705A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
TWI624268B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DK125693D0 (https=) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
AU709633B2 (en) 1995-04-26 1999-09-02 Children's Medical Center Corporation Angiostatin fragments and aggregate angiostatin and methods of use
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5955627A (en) 1996-12-16 1999-09-21 Kuraray Co., Ltd. Process for the preparation of cyclopropylacetylene derivatives
EP1001985A1 (en) * 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
JP3561154B2 (ja) 1997-12-26 2004-09-02 株式会社東芝 放送受信装置および契約管理装置
US6728260B2 (en) 1998-06-26 2004-04-27 Intel Corporation Switch and/or router unit
ATE349226T1 (de) 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
CA2360690A1 (en) 1999-01-28 2000-08-03 Michael S. O'reilly Plasminogen kringle 4 region fragments and methods of use
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20030014787P1 (en) 1999-03-31 2003-01-16 Olesen L. Pernille Floribunda rose variety 'POULfeld'
JP2003524413A (ja) 1999-10-07 2003-08-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド プラスミノーゲン様ポリヌクレオチド、ポリペプチド、および抗体
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US6596785B2 (en) 2001-07-17 2003-07-22 Foamex L.P. Ink retaining foam structure
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003210137A1 (en) 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US7075933B2 (en) 2003-08-01 2006-07-11 Nortel Networks, Ltd. Method and apparatus for implementing hub-and-spoke topology virtual private networks
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
CN102660564B (zh) 2004-04-22 2013-05-08 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
JP2008510814A (ja) 2004-08-23 2008-04-10 ワイス Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US8064439B2 (en) 2005-06-30 2011-11-22 Cisco Technology, Inc. Method and system for call processing
CN101263115A (zh) 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
CN101842093B (zh) * 2007-10-23 2012-08-22 株式会社医药分子设计研究所 Pai-1产生抑制剂
PL2220221T3 (pl) * 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US20090208448A1 (en) * 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
EP2424561A2 (en) 2009-04-30 2012-03-07 Catherine Blondel Methods for treating ocular conditions
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US9644196B2 (en) * 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
DK2914575T3 (da) * 2012-10-31 2021-01-18 Univ Michigan Regents Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
TN2016000048A1 (en) * 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CN104789544B (zh) * 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CA3008185C (en) 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
WO2018107688A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
EP3725326B1 (en) 2017-12-15 2026-04-22 Talengen International Limited Plasminogen for treating osteoarthritis

Similar Documents

Publication Publication Date Title
JP2020502150A5 (https=)
Raskin et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
JP2020502151A5 (https=)
Seyed Ahmadi et al. The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: a randomized clinical trial (GOLD-4)
Heise et al. Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double‐blind, crossover trial
Giorgino et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
Jadzinsky et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
JP2020502140A5 (https=)
Iqbal et al. Recent updates on type 1 diabetes mellitus management for clinicians
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
JP2015164964A5 (https=)
De Caterina et al. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options
AU2012328388A1 (en) Treatment protocol of diabetes type 2
JP2006515625A5 (https=)
CN110139667A (zh) 一种使胰高血糖素、胰岛素恢复正常平衡的方法
JP2020510628A5 (https=)
Hollander et al. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study)
KR20240027053A (ko) 마즈두타이드의 용도
Jain et al. Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes
Khetarpal et al. Impact of different intravenous fluids on blood glucose levels in nondiabetic patients undergoing elective major noncardiac surgeries
CN108135918A (zh) Glp-1分泌促进剂
Ikushima et al. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
Dailey Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review
Juneja Hyperglycemia management in the hospital: about glucose targets and process improvements
Sharma et al. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study